Global Bacterial Conjunctivitis Market

Market Insights

The drivers responsible for the deep market penetration of drugs utilized for the treatment of bacterial conjunctivitis are the rising prevalence of bacterial conjunctivitis, water and air pollution, and a lack of personal hygiene. Technological advancements in drug development, such as ISV-405 (Azithromycin 2.0%), have resulted in immediate relief because the dose required is minimal, and thus fewer drug-related adverse events. A strong limitation of bacterial conjunctivitis is that the number of parameters that can be detected is very limited, and the overlap of symptoms between adenoviral and bacterial conjunctivitis is ambiguous, resulting in an ineffective dosage regimen.

For the purpose of this study, the various products studied include fluoroquinolones, aminoglycosides, macrolides, and others. The fluoroquinolones are classified as Ciprofloxacin, Ofloxacin, Levofloxacin, Moxifloxacin, Gatifloxacin, and Besifloxacin. Aminoglycosides are further classified as Tobramycin and Gentamycin. Macrolides are divided into two types: erythromycin and azithromycin. Others consist of phenols, glycolipopeptides, and cyclic polypeptides. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

The geographic segmentation of the global bacterial conjunctivitis market is performed for the regions of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global bacterial conjunctivitis market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the global bacterial conjunctivitis market. The major players in the bacterial conjunctivitis market are Actavis Plc., Akorn, Inc., Bayer AG, F. Hoffman La-Roche Ltd., InSite Vision Incorporated, Merck & Co., Inc., Novartis AG, Perrigo Company Plc., Pfizer, Inc., and Santen Pharmaceutical Co., Ltd.

Based on drug class, the global bacterial conjunctivitis market is categorized into:

• Fluoroquinolones

• • Ciprofloxacin
  • Ofloxacin
  • Levofloxacin
  • Moxifloxacin
  • Gatifloxacin
  • Besifloxacin
• Aminoglycosides
  • Tobramycin
  • Gentamycin
• Macrolides
  • Erythromycin
  • Azithromycin
• Others (phenols, glycolipopetides, cyclic polypeptides)

The bacterial conjunctivitis market is driven by factors such as pharmaceutical R&D focusing on the treatment of bacterial conjunctivitis, rising public awareness, and alliances between pharmaceutical giants and research institutes. Furthermore, the increasing prevalence of bacterial conjunctivitis, as well as increased air and water pollution, have an impact on the conjunctiva of the eye. In 2016, the fluoroquinolones segment held the largest market share, chiefly due to factors such as the broad spectrum antimicrobial activity offered by fluoroquinolones against gram-positive, gram-negative, and anaerobic organisms. Because of advances in drug formulation technology, current-generation fluoroquinolones such as gatifloxacin, moxifloxacin, and besifloxacin are now the first line of treatment. The impending patent expiration of blockbuster-branded fluoroquinolone drugs is one of this segment’s limitations throughout the forecast period. Aminoglycosides and macrolides together will be the fastest-growing segment throughout the forecast period of 2017–2025. Factors contributing to the growth of this segment are increasing incidences of antibiotic-related drug resistance in bacterial conjunctivitis patients and technological advancement with effective clinical trials conducted to analyze safety and efficacy related to the drug formulation of antibiotics at different concentrations, resulting in immediate relief due to a faster onset of action. The major players in the bacterial conjunctivitis market are Actavis Plc., Akorn, Inc., Bayer AG, F. Hoffman La-Roche Ltd., InSite Vision Incorporated, Merck & Co., Inc., Novartis AG, Perrigo Company Plc., Pfizer, Inc., and Santen Pharmaceutical Co., Ltd.

For the purpose of this study, the global bacterial conjunctivitis market is categorized into the following regional and country-specific markets:

• North America

• • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • rest of Latin America
• Middle East and Africa
  • GCC
  • Rest of the Middle East and Africa

In the base year 2016, North America was observed to be the largest market for bacterial conjunctivitis. According to the National Eye Institute, in 2016, about 3 million cases of bacterial conjunctivitis were reported. The dominance of North America is mainly attributed to the presence of key drivers, such as the rising prevalence of bacterial conjunctivitis, the existence of developed research and healthcare institutions, and an affordable reimbursement scenario. The market growth in Europe is mainly attributed to the rising prevalence of air and water pollution and the presence of pharmaceutical giants pioneering the treatment of bacterial conjunctivitis. Asia Pacific was observed as the fastest-growing regional segment throughout the forecast period of 2017–2025. Factors that are anticipated to propel market growth are increasing disposable income and a supportive regulatory environment for bacterial conjunctivitis products. Moreover, factors such as developing health infrastructure and business expansion by pharmaceutical giants in untapped markets with unmet medical needs are going to fuel the rapid growth of the bacterial conjunctivitis market in Latin America, the Middle East, and Africa in the near future.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Bacterial Conjunctivitis Market Portraiture
2.1.1. Global Bacterial Conjunctivitis Market, by Drug Class, 2016
2.1.2. Global Bacterial Conjunctivitis Market, by Geography, 2016

Chapter 3. Bacterial Conjunctivitis: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Bacterial Conjunctivitis Market, by Drug Class, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Bacterial Conjunctivitis Market, by Drug Class
4.3. Fluoroquinolones
4.3.1. Ciprofloxacin
4.3.2. Ofloxacin
4.3.3. Levofloxacin
4.3.4. Moxifloxacin
4.3.5. Gatifloxacin
4.3.6. Besifloxacin
4.4. Aminoglycosides
4.4.1. Tobramycin
4.4.2. Gentamycin
4.5. Macrolides
4.5.1. Erythromycin
4.5.2. Azithromycin
4.6. Others (Phenicols, Glycolipopeptides, Cyclic Polypeptides)

Chapter 5. Global Bacterial Conjunctivitis Market, by Product Pipeline
5.1. Overview
5.2. Phase III Drug – Till 2025 (US$ Mn)
5.2.1. Vancomycin 1.1% Ointment
5.3. Phase II Drug (Qualitative Information)
5.3.1. PRO – 157

Chapter 6. Global Bacterial Conjunctivitis Market, by Geography, 2015 – 2025 (US$ Mn)
6.1. Overview
6.2. North America Bacterial Conjunctivitis Market Analysis, 2015 – 2025
6.2.1. North America Bacterial Conjunctivitis Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.2.2. North America Bacterial Conjunctivitis Market, by Country, 2015 – 2025 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe Bacterial Conjunctivitis Market Analysis, 2015 – 2025
6.3.1. Europe Bacterial Conjunctivitis Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.3.2. Europe Bacterial Conjunctivitis Market, by Country, 2015 – 2025 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific Bacterial Conjunctivitis Market Analysis, 2015 – 2025
6.4.1. Asia Pacific Bacterial Conjunctivitis Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.4.2. Asia Pacific Bacterial Conjunctivitis Market, by Country, 2015 – 2025 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. India
6.4.2.4. Rest of APAC
6.5. Latin America Bacterial Conjunctivitis Market Analysis, 2015 – 2025
6.5.1. Latin America Bacterial Conjunctivitis Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.5.2. Latin America Bacterial Conjunctivitis Market, by Country, 2015 – 2025 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Bacterial Conjunctivitis Market Analysis, 2015 – 2025
6.6.1. MEA Bacterial Conjunctivitis Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.6.2. MEA Bacterial Conjunctivitis Market, by Region, 2015 – 2025 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Actavis Plc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Akorn, Inc.
7.3. Bayer AG
7.4. F.Hoffman La-Roche Ltd.
7.5. InSite Vision Incorporated
7.6. Merck & Co., Inc.
7.7. Novartis AG
7.8. Perrigo Company Plc.
7.9. Pfizer, Inc.
7.10. Santen Pharmaceutical Co., Ltd.
7.11. Other Notable Players

List of Figures

FIG. 1 Bacterial Conjunctivitis: Market Segmentation
FIG. 2 Global Bacterial Conjunctivitis Market Share, by Drug Class, 2016 (Value %)
FIG. 3 Global Bacterial Conjunctivitis Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global Ciprofloxacin Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global Ofloxacin Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Levofloxacin Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Moxifloxacin Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Gatifloxacin Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Besifloxacin Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Tobramycin Market, 2015 – 2025 (US$ Mn)
FIG. 13 Global Gentamycin Market, 2015 – 2025 (US$ Mn)
FIG. 14 Global Erythromycin Market, 2015 – 2025 (US$ Mn)
FIG. 15 Global Azithromycin Market, 2015 – 2025 (US$ Mn)
FIG. 16 Global Other Drug Class for Bacterial Conjunctivitis Market, 2015 – 2025 (US$ Mn)
FIG. 17 Global Phase III Drug Market for Bacterial Conjunctivitis, Till – 2025 (US$ Mn)
FIG. 18 U.S. Bacterial Conjunctivitis Market, 2015 – 2025 (US$ Mn)
FIG. 19 Canada Bacterial Conjunctivitis Market, 2015 – 2025 (US$ Mn)
FIG. 20 U.K. Bacterial Conjunctivitis Market, 2015 – 2025 (US$ Mn)
FIG. 21 Germany Bacterial Conjunctivitis Market, 2015 – 2025 (US$ Mn)
FIG. 22 Rest of Europe Bacterial Conjunctivitis Market, 2015 – 2025 (US$ Mn)
FIG. 23 Japan Bacterial Conjunctivitis Market, 2015 – 2025 (US$ Mn)
FIG. 24 China Bacterial Conjunctivitis Market, 2015 – 2025 (US$ Mn)
FIG. 25 India Bacterial Conjunctivitis Market, 2015 – 2025 (US$ Mn)
FIG. 26 Rest of Asia Pacific Bacterial Conjunctivitis Market, 2015 – 2025 (US$ Mn)
FIG. 27 Brazil Bacterial Conjunctivitis Market, 2015 – 2025 (US$ Mn)
FIG. 28 Mexico Bacterial Conjunctivitis Market, 2015 – 2025 (US$ Mn)
FIG. 29 Rest of Latin America Bacterial Conjunctivitis Market, 2015 – 2025 (US$ Mn)
FIG. 30 GCC Bacterial Conjunctivitis Market, 2015 – 2025 (US$ Mn)
FIG. 31 Rest of Middle East and Africa Bacterial Conjunctivitis Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Bacterial Conjunctivitis Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 2 Global Fluoroquinolones Market for Bacterial Conjunctivitis, 2015 – 2025 (US$ Mn)
TABLE 3 Global Aminoglycosides Market for Bacterial Conjunctivitis, 2015 – 2025 (US$ Mn)
TABLE 4 Global Macrolides Market for Bacterial Conjunctivitis, 2015 – 2025 (US$ Mn)
TABLE 5 Global Bacterial Conjunctivitis Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 6 North America Bacterial Conjunctivitis Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 7 North America Bacterial Conjunctivitis Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 8 Europe Bacterial Conjunctivitis Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 9 Europe Bacterial Conjunctivitis Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Asia Pacific Bacterial Conjunctivitis Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 11 Asia Pacific Bacterial Conjunctivitis Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 12 Latin America Bacterial Conjunctivitis Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 13 Latin America Bacterial Conjunctivitis Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 14 Middle East and Africa Bacterial Conjunctivitis Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 15 Middle East and Africa Bacterial Conjunctivitis Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 16 Actavis Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Akorn, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 F.Hoffman La-Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 InSite Vision Incorporated.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Perrigo Company Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 Pfizer, Inc..: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Santen Pharmaceutical Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)